# GSK6853

| | |
|---|---|
| **Cat. No.:** | HY-100220 |
| **CAS No.:** | 1910124-24-1 |
| **Molecular Formula:** | $C_{22}H_{27}N_5O_3$ |
| **Molecular Weight:** | 409.48 |
| **Target:** | Epigenetic Reader Domain |
| **Pathway:** | Epigenetics |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 2 years<br>-20°C 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 25 mg/mL (61.05 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.4421 mL | 12.2106 mL | 24.4212 mL |
| 5 mM | 0.4884 mL | 2.4421 mL | 4.8842 mL |
| 10 mM | 0.2442 mL | 1.2211 mL | 2.4421 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.11 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.11 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.11 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

GSK6853 is a potent and selective inhibitor of the BRPF1 bromodomain. GSK6853 shows excellent BRPF1 potency ($pK_d$=9.5) and greater than 1600-fold selectivity over all other bromodomains[1].

**In Vivo**

The ip route of administration would be suitable for dosing GSK6853 in potential PK/PD models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Bamborough P et al. GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. ACS Med Chem Lett. 2016 May 9;7(6):552-7.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA